DiMarchi R - Search Results

1

Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group.

Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Anderson JH Jr, et al. Among authors: dimarchi r. Clin Ther. 1997 Jan-Feb;19(1):62-72. doi: 10.1016/s0149-2918(97)80073-2. Clin Ther. 1997. PMID: 9083709 Clinical Trial.

2

Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I.

DiMarchi RD, Chance RE, Long HB, Shields JE, Slieker LJ. DiMarchi RD, et al. Horm Res. 1994;41 Suppl 2:93-6. doi: 10.1159/000183967. Horm Res. 1994. PMID: 8088710 Review.

3

Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group.

Anderson JH Jr, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, DiMarchi R. Anderson JH Jr, et al. Among authors: dimarchi r. Diabetes. 1997 Feb;46(2):265-70. doi: 10.2337/diab.46.2.265. Diabetes. 1997. PMID: 9000704 Clinical Trial.

4

Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Anderson JH Jr, et al. Among authors: dimarchi r. Arch Intern Med. 1997 Jun 9;157(11):1249-55. Arch Intern Med. 1997. PMID: 9183237 Clinical Trial.

5

Basal activity profiles of NPH and [Nepsilon-palmitoyl Lys (B29)] human insulins in subjects with IDDM.

Radziuk J, Pye S, Bradley B, Braaten J, Vignati L, Roach P, Bowsher R, DiMarchi R, Chance R. Radziuk J, et al. Among authors: dimarchi r. Diabetologia. 1998 Jan;41(1):116-20. doi: 10.1007/s001250050876. Diabetologia. 1998. PMID: 9498640

6

Insulin analogues and their potential in the management of diabetes mellitus.

Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Bolli GB, et al. Diabetologia. 1999 Oct;42(10):1151-67. doi: 10.1007/s001250051286. Diabetologia. 1999. PMID: 10525654 Review. No abstract available.

7

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.

Frias JP, Bastyr EJ 3rd, Vignati L, Tschöp MH, Schmitt C, Owen K, Christensen RH, DiMarchi RD. Frias JP, et al. Cell Metab. 2017 Aug 1;26(2):343-352.e2. doi: 10.1016/j.cmet.2017.07.011. Cell Metab. 2017. PMID: 28768173 Free article. Clinical Trial.

8

pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity.

Kohn WD, Micanovic R, Myers SL, Vick AM, Kahl SD, Zhang L, Strifler BA, Li S, Shang J, Beals JM, Mayer JP, DiMarchi RD. Kohn WD, et al. Among authors: dimarchi rd. Peptides. 2007 Apr;28(4):935-48. doi: 10.1016/j.peptides.2007.01.012. Epub 2007 Jan 25. Peptides. 2007. PMID: 17328992

9

Insulin structure and function.

Mayer JP, Zhang F, DiMarchi RD. Mayer JP, et al. Biopolymers. 2007;88(5):687-713. doi: 10.1002/bip.20734. Biopolymers. 2007. PMID: 17410596 Review.

10

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

Finan B, Ma T, Ottaway N, Müller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, Bruemmer D, Drucker DJ, Pfluger PT, Perez-Tilve D, Gidda J, Vignati L, Zhang L, Hauptman JB, Lau M, Brecheisen M, Uhles S, Riboulet W, Hainaut E, Sebokova E, Conde-Knape K, Konkar A, DiMarchi RD, Tschöp MH. Finan B, et al. Sci Transl Med. 2013 Oct 30;5(209):209ra151. doi: 10.1126/scitranslmed.3007218. Sci Transl Med. 2013. PMID: 24174327 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

207 results

Search Page